Management ChangeJul 8, 2026, 06:31 AM
Perspective Therapeutics Appoints Paul Lyne as CSO; Schultz Transitions
AI Summary
Perspective Therapeutics, Inc. announced the appointment of Paul Lyne, Ph.D., as its new Chief Science Officer. Concurrently, co-founder and long-time CSO, Michael K. Schultz, Ph.D., has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned retirement. The company expects Dr. Lyne's extensive experience in oncology research and drug development to accelerate its scientific strategy and pipeline advancement, while Dr. Schultz's continued advisory role will ensure ongoing scientific guidance.
Key Highlights
- Paul Lyne, Ph.D., appointed as Chief Science Officer.
- Michael K. Schultz, Ph.D., transitions to Senior Scientific Advisor & Co-Founder.
- Dr. Lyne brings over 25 years of pharmaceutical and biotechnology industry experience.
- Dr. Lyne previously served as Senior Vice President and Head of Oncology Research at Merck KGaA.
- Dr. Schultz co-founded Perspective Therapeutics and will continue to provide insight in an advisory role.
Price Impact
More from CATX